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Background: Hermansky-Pudlak syndrome 2 (HPS2; OMIM #608233) is a rare, autosomal recessive disorder caused
by loss-of-function genetic variations affecting AP3B1, which encodes the β3A subunit of the adaptor-related
protein complex 3 (AP3). Phenotypic characteristics include reduced pigmentation, absent platelet dense granule
secretion, neutropenia and reduced cytotoxic T lymphocyte (CTL) and natural killer (NK) cell function. To date HPS2
has been associated with non-synonymous, stop-gain or deletion-insertion nucleotide variations within the coding
region of AP3B1.
Case presentation: We describe a consanguineous female infant with reduced pigmentation, neutropenia and
recurrent infections. Platelets displayed reduced aggregation and absent ATP secretion in response to collagen and
ADP, indicating a platelet dense granule defect. There was increased basal surface expression of CD107a (lysosome-
associated membrane protein 1(LAMP-1)) on NK cells and CTLs from the study subject and a smaller increase in the
percentage of CD107a positive cells after stimulation compared to most healthy controls. Immunoblotting of
protein extracts from EBV-transformed lymphoblasts from the index case showed absent expression of full-length
AP-3 β3A subunit protein, confirming a phenotypic diagnosis of HPS2.
The index case displayed a homozygous pericentric inv(5)(p15.1q14.1), which was also detected as a heterozygous
defect in both parents of the index case. No loss of genetic material was demonstrated by microarray comparative
genome hybridisation at 60kb resolution. Fluorescence in-situ hybridisation using the 189.6kb probe RP11-422I12,
which maps to 5q14.1, demonstrated dual hybridisation to both 5q14.1 and 5p15.1 regions of the inverted Chr5.
The RP11-422I12 probe maps from intron 1 to intron 16 of AP3B1, thus localising the 5q inversion breakpoint to
within AP3B1. The probe RP11-211K15, which corresponds to an intergenic region on 5p also showed dual
hybridisation, enabling localisation of the 5p inversion breakpoint.
Conclusion: This case report extends the phenotypic description of the very rare disorder HPS2. Our demonstration
of a homozygous Chr5 inversion predicted to disrupt AP3B1 gene provides a novel pathogenic mechanism for this
disorder.
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Hermansky-Pudlak syndrome (HPS) is a group of genet-
ically heterogeneous disorders that are caused by muta-
tions in genes that affect the synthesis and function of
lysosome-related organelles (LRO) [1,2]. LRO are
specialised structures that have the ultra-structural and
functional characteristics of lysosomes but serve as
secretory granules in some cell types. They are widely
distributed in haematopoietic and other tissues and
include melanosomes in melanocytes, dense granules in
platelets, lamellar bodies in alveolar type II epithelial
cells, azurophilic granules in neutrophils and lyticA B
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Figure 1 Clinical and laboratory phenotype of the index case. Pedigre
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and immunodeficiency [1,2].
HPS type 2 (HPS2) is a very rare subtype of HPS in
which reduced pigmentation and platelet dysfunctionD
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cases, reduced CTL and NK cell cytotoxicity. This may
manifest as increased susceptibility to viral infection and
rarely, haemophagocytic lymphohistiocytosis (HLH) in
response to viral infection [7,8,12]. HPS2 has previously
been associated with loss-of-function nucleotide varia-
tions in AP3B1 that encodes the β3A-subunit of the
adaptor protein complex 3 (AP-3) [11]. AP-3 is essential
for trafficking cargo proteins to LRO. Consequently,
proteins such as CD63 and LAMP-1, which are normally
targeted to the lysosome compartment in haematopoi-
etic cells, are incorrectly trafficked to the cell surface
and accumulate in endosomes [4]. In all the previous re-
ports of HPS2, loss of AP-3 β3A-subunit expression is
associated with missense, nonsense or deletion-insertion
nucleotide variations within AP3B1. Here we report the
clinical and laboratory phenotype of a new index case
with HPS2 associated with a homozygous pericentric
inversion of Chr5. We demonstrate that the 5q inversion
breakpoint lies within AP3B1 thus providing a new
mechanistic explanation for the HPS2 phenotype.
Case presentation
The index case is a female child of Lebanese origin (P1)
with healthy consanguineous parents and two healthy
older siblings (Figure 1A). She displayed reduced skin,
hair and iris pigmentation compared to parents and
siblings but was not dysmorphic (Figure 1B). Her clinical
course has been dominated by recurrent severe febrile
illnesses, including episodes of documented adenovirus
and respiratory syncytial virus infection, on one occa-
sion requiring ventilation on paediatric intensive care.
At presentation, the index case was noted to have
hepatosplenomegaly and fever, but had no other
features of haemophagocytic syndrome (normal serum
triglyceride and ferritin concentration and no morpho-
logical evidence of haemophagocytosis on a bone
marrow aspirate). A high-resolution CT chest scan at
34 months old demonstrated patchy ground glass
shadowing and interlobular septal thickening in the
lower lobes suggestive of early stage pulmonary fibro-
sis. After follow up to 36 months, there have been no
reported symptoms of abnormal bleeding or colitis.
Laboratory investigations revealed that P1 had persist-
ent neutropenia (typically 0.2 × 109/l; reference interval
1.5-7.0 × 109/l), with normal neutrophil morphology in
peripheral blood. Serum concentrations of immuno-
globulin subclasses were normal and there were satisfac-
tory antibody responses to childhood immunisations for
haemophilus, tetanus and the 7-valent pneumococcal anti-
gen suggesting normal B-lymphocyte function. Platelet
impedance aggregation and secretion responses were moni-
tored simultaneously using a CHRONO-LOG model 700
lumiaggregometer. Platelets from P1 displayed partialaggregation to 5 μg/ml collagen (maximum aggregation
(MA) MA 14 Ω) and to 10 μM ADP (MA 9 Ω) whereas
these agonists induced full aggregation of control platelets
(MA 21 Ω and 24 Ω with 5 μg/ml collagen 10 μM ADP re-
spectively; Figure 1C). There was brisk ATP secretion from
control platelets in response to 5 μg/ml collagen and to10
μM ADP (2.34 nmol and 1.06 nmol ATP respectively).
However, platelet ATP secretion was absent in P1 when
stimulated with these agonists, indicating defective platelet
dense granule release (Figure 1C).
A FACS-based granule release assay (GRA), using the
surface expression of CD107a (lysosome-associated
membrane protein 1 (LAMP-1)) as a marker of lytic
granule exocytosis, was used to assess CTL and NK cells
in a resting state, and after stimulation with anti-CD3 or
phytohaemagglutinin respectively [14,15]. Granule secre-
tion was determined by measuring the increase in the
percentage of CD107a positive cells, determined from
100,000 events, in the resting state versus activated state.
The percentage of CD107a positive NK cells in the rest-
ing state was higher in P1 (5.4%) compared to a healthy
control (HC) measured in parallel (0.9%; Additional
file 1: Figure S1). After cell stimulation, the proportion
of CD107a positive CTL and NK cells from P1 increased
by 0.8% and 5.5% respectively. These responses were
within the lowest quartile of the 95% reference interval
of responses determined at our laboratory by testing
39 healthy controls (Figure 1D).
As this clinical and laboratory phenotype was consistent
with HPS2, immunoblots were performed to determine
the expression level of the AP3 β3A-subunit in EBV-
immortalised B lymphoblastoid cells from P1 (Prepared
by the Health Protection Agency Culture Collections,
Salisbury, UK). Cell lysates were resolved by electropho-
resis on a sodium dodecyl sulphate-polyacrylamide gel
(SDS-PAGE) and were immunoblotted with a rabbit poly-
clonal anti-β3A antibody (a gift from Professor Margaret
Robinson, University of Cambridge) and a control rabbit
polyclonal anti-GAPDH (Santa Cruz). In positive control
cell lysates prepared from fresh healthy donor lympho-
cytes, immunoblotting demonstrated a single protein band
of approximate molecular weight 123 kDa that is the
expected molecular weight of the AP3 β3A-subunit. In
contrast, there was no detectible full length AP3 β3A-
subunit in lymphoblastoid cells from P1, or in a negative
control lymphoblastoid cell lysates obtained from a previ-
ously reported patient with HPS2 [12] (Figure 1E).
Karyotype analysis of peripheral blood leukocyte meta-
phases from P1 demonstrated a pericentric inversion of
Chr5, initially estimated to be inv(5)(p15.1q13.3), that
was present in all observed Chr5, indicating a homozygous
defect. An identical inversion of Chr5 was identified in het-
erozygous form in the asymptomatic mother of the index
case (P2; Figure 1A and 2A). Microarray comparative
BRP11-211K15 RP11-442I12C D
5p15.1 5q14.1
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AP3B1
RP11-442I12
i1i16
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AP3B1 translation
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Figure 2 Pericentric inversion of chromosome 5. Partial ideogram of a metaphase from the bone marrow aspirate from P2 showing both the
normal and abnormal Chr5 with an inversion estimated to be between cytobands 5p15.1 and 5q13.3 (A). Schematic diagram of Chr5 showing
the normal cytoband localization of the fluorescence in situ hybridisation (FISH) probes RP11-211K15 and RP11-422I12 (B). RP11-211K15 maps to
an intergenic region at 5p15.1. RP11-422I12 maps to 5q14.1, and spans intron 1 to intron 16 of AP3B1. FISH was performed on metaphase
chromosomes from P2, who was a heterozygote carrier of the inverted Chr5 (C and D). The images show DAPI stained chromosomes labelled
with pGA-16 (green signal) which is a centromere marker of Chr5 and Chr9. The 5p15.1 probe RP11-211K15 (C; red signal) correctly localises to
5p15.1 in the normal Ch5 (solid arrow) but showed dual hybridisation to 5q14.1 and 5p15.1 in the inverted Chr5 (broken arrows). The 5q14.1
probe RP11-422I12 (D; red signal) correctly localises to 5q14.1 in the normal Ch5 (solid arrow) but showed dual hybridisation to 5p15.1 and
5q14.1 in the inverted Chr5 (broken arrows).
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ISCA (International Standards for Cytogenomic Arrays)
Consortium 8 × 60K version 2.0 probe set showed no
loss of genetic material at 60 kb resolution, suggesting
that the inversion was balanced (Additional file 2:
Figure S2).
AP3B1, which encodes the AP-3 β3A-subunit, lies at
cytoband 5q14.1 in the region of the initially estimated
5q inversion breakpoint. Therefore, we used fluorescence
in-situ hybridisation (FISH) using probes prepared from
the Sanger 30 kb EnsEMBL clone set to fine map both
inversion breakpoints in metaphases prepared from P2,
who displayed both normal and inverted Chr5. The hy-
bridisation signal from the probe RP11-317N14 (NCBI36 nomenclature), which maps telomeric from AP3B1
intron (i) 6 to include exons (e)1-6 and the 5’ flanking
sequence correctly localised to q14.1 of the inverted
Chr5. However, hybridisation signals from probe RP11-
59M8 (AP3B1 i7 to i22), and probe RP11-51E14 (centro-
meric from AP3B1 i17 to include e18-e26 and the
30- flanking sequence) localized to 5p similar to the inv(5)
(p15.1q13.3) observed in the initial diagnostic karyotype.
Together, these observations suggested that the 5q break-
point lay within AP3B1. This was confirmed by the
detection of hybridisation signal from RP11-422I12 (AP3B1
i1 to i16 (Chr5:77417815–77569358)) at both q14.1 and
p15.1 of the inverted Chr5 but only at 5q in the normal
Chr5 (Figure 2B and 2D).
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lar strategy. In this analysis, the probe RP11-211K15,
which maps to Chr5:18263045–18430126 within 5p15.1
displayed dual hybridisation to both the cytobands
5p15.1 and 15q14.1, consistent with the karyotype find-
ings. RP11-211K15 maps to a genomic region on 5p that
contains no identifiable genes in the RefSeq, UCSC or
GENCODE databases (Figure 2B and 2C).
Conclusions
We describe a new index case with reduced pigmenta-
tion and a platelet dense granule defect indicating an
HPS group disorder. In addition, there was a clinical im-
munodeficiency phenotype, a persistent neutropenia and
radiographic evidence suggestive of early pulmonary
fibrosis. This phenotype was indicative of HPS2, which
we confirmed by showing absent expression of AP-3
β3A subunit in lymphocytes by immunoblotting. It is
noteworthy that the index case also displayed increased
surface expression of lytic granule markers in resting
CTL and NK cells and diminished granule release
consistent with mis-trafficking of lytic granules. This is
similar to, but less marked than in other secretopathies
such as Chediak Higashi syndrome (OMIM #214500),
Griscelli syndrome (OMIM #607624), and Familial
haemophagocytic lymphohistiocytosis disorders (OMIM
#608898 and #613101), which may be complicated by epi-
sodes of haemophagocytic syndrome in response to viral
infection [16-18]. This is in keeping with other clinical de-
scriptions of HPS2 in which haemophagocytic syndrome
has been reported in only a minority of cases [7,8,12].
To date, the molecular pathogenesis of HPS2 has been
reported in only 13 index cases. In these individuals, a
total of 14 nucleotide variations within AP3B1 have been
identified, in all cases occurring as homozygous or
compound heterozygous traits. These include 5 short
deletion variations [10,12,19]; 3 nonsense single nucleo-
tide variations (SNV) [7,9]; 2 insertions [8,20]; 2 splice
site SNV [20,21]; 1 missense SNV [11] and 1 complex
deletion-insertion [8], all of which are predicted to
prevent expression of the AP-3 β3A subunit. Our finding
that a previously unreported homozygous pericentric
inversion (inv(5)(p15.1q14.1) was also associated with
the HPS2 phenotype extends the repertoire of genetic
variations associated with this disorder. We also demon-
strated that the FISH probe RP11-422I12 hybridised to
both the cytobands 5q14.1 and 5p15.1 thus localising the
inversion breakpoint to within the boundaries of this
probe. Since RP11-422I12 maps to AP3B1 intron 1 to in-
tron 16, the inversion necessarily lies within AP3B1 and
is predicted to disrupt gene expression. We cannot rule
out the possibility of loss of genetic material within these
boundaries in AP3B1 related to the inversion. However,
the array cGH data indicate that if any deletion occurredit is likely to be at less than 60kb size. Since we also
mapped the 5p inversion breakpoint to a region of
5p15.1 that contained no CCDS-annotated genes, it is
likely that the phenotype of the index case arose only
from disruption of AP3B1 at the 5q inversion break-
point. This represents a novel molecular mechanism
for HPS2.
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Additional file
Additional file 1: Figure S1. Granule release assay (GRA) results are
shown for a normal healthy control (HC) and the index case (P1) for
cytotoxic T-cells (CTLs) (A) and natural killer (NK) cells (B). Peripheral
blood mononuclear cells were stimulated overnight with interleukin 2
followed by incubation with fluorescently-labelled anti-CD107a (LAMP-1)
alone (resting; left panel A & B) or with anti-CD3 antibody to activate
CTLs (right panel A) or phytohaemagglutinin (PHA) to activate NK cells
(right panel B). Samples were analysed by flow cytometry, gating on
lymphocytes by forward/side scatter. CD107a expression was analysed on
CTLs and NK cells and the %CD107a + cells are indicated in each
histogram. The increase in percentage of CD107a + cells (Δ %CD107a+)
between resting and stimulated cells was determined.
Additional file 2: Figure S2. Microarray comparative genome
hybridisation profile of Chr5 from P1 (A). The expected position of signal
from any loss of genetic material in the profile is indicated by (-) and
potential gain of material is indicated by (+). A Chr 5 ideogram (B) is
shown for comparison.
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